Lexicon (LXRX) announced that patient screening has been completed in the Phase 2b PROGRESS clinical trial evaluating the company’s AAK1 inhibitor, LX9211, for the treatment of Diabetic Peripheral Neuropathic Pain, and the company expects to complete enrollment of adult T1D or T2D patients suffering from moderate to severe DPNP ahead of schedule, and report topline data in 1Q25, instead of 2Q25, H.C. Wainwright tells investors in a research note. The firm is “glad” PROGRESS is moving ahead in a timely manner and looks forward to updates about enrollment, dosing, and data updates. H.C. Wainwright made no change to its Buy rating or $10 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon completes screening in Phase 2B progress study of LX9211
- Lexicon signs licensing agreement with Viatris for sotagliflozin
- Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license
- Lexicon to present Phase 3 trial design for sotagliflozin in HCM
- Lexicon announces departure of President, COO Jeff Wade